Epitel raises $26M Series B to scale wireless, at-home EEG monitoring

What's the deal? Epitel, a Salt Lake City-based maker of AI-driven wireless brain health technology, has raised a $26 million Series B co-led by Catalyst Health VenturesDealroom has a profile for this one. Try Dealroom → and Genoa VenturesDealroom has a profile for this one. Try Dealroom →. New and existing investors also joined the round.

What's the endgame? The money will expand commercial rollout of Epitel's REMI Remote EEG Monitoring System, which uses wireless, wearable sensors to track brain activity at home for several weeks. Its Vigilenz AI flags potential seizures to help clinicians review extended recordings and speed up diagnosis.

Why now? In the US, 9.2 million Americans experience seizures annually, yet 40% lack access to EEG — in part because only 27% of US hospitals have EEG capacity. Traditional EEG typically monitors patients for up to three days, while seizures can occur days or weeks apart, meaning a diagnosis can take months.

Epitel's REMI portfolio has secured five US Food and Drug Administration 510(k) clearances. The platform is cleared for neurological monitoring in patients as young as one year old, with AI-assisted event detection available from age six.

What's the money for? The capital will fund three priorities: expanding commercial infrastructure across sales, marketing, and customer experience; streamlining distribution to ease provider adoption; and growing ambulatory market access, now that FDA clearance reaches patients as young as one year old.

Read more: AP News